Research Topics
| Michael HonerSummaryAffiliation: Paul Scherrer Institute Country: Switzerland Publications
| Collaborators
|
Detail Information
Publications
Anti-Angiogenic/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG/FLT-PETMichael Honer
Center for Radiopharmaceutical Science, Eidgenoessische Technische Hochschule, Zurich, Switzerland
Transl Oncol 3:264-75. 2010..These conclusions warrant clinical testing...
Dynamic imaging of striatal D2 receptors in mice using quad-HIDAC PETMichael Honer
Center for Radiopharmaceutical Science, Paul Scherrer Institute, Villigen, Switzerland
J Nucl Med 45:464-70. 2004..The aim of this study was to establish the tomograph's utility in a biologic application and to demonstrate the feasibility of rapid dynamic neuroreceptor imaging in mice...- Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasisKarin Knogler
Center for Radiopharmaceutical Science, ETH PSI USZ, Paul Scherrer Institute, CH 5232 Villigen, Switzerland
Clin Cancer Res 13:603-11. 2007..We examined the tumor-targeting and therapeutic effects of (67)Cu-labeled single amino acid mutant forms of anti-L1 monoclonal antibody chCE7 in nude mice with orthotopically implanted SKOV3ip human ovarian carcinoma cells... - Targeting of renal carcinoma with 67/64Cu-labeled anti-L1-CAM antibody chCE7: selection of copper ligands and PET imagingKurt Zimmermann
Center for Radiopharmaceutical Science ETH-PSI-USZ, Paul Scherrer Institute, CH-5232 Villigen, Switzerland
Nucl Med Biol 30:417-27. 2003..High resolution PET imaging with (64)Cu-CPTA-labeled MAb chCE7 showed uptake in lymph nodes and heterogeneous distribution in tumor xenografts... - In vivo evaluation of 177Lu- and 67/64Cu-labeled recombinant fragments of antibody chCE7 for radioimmunotherapy and PET imaging of L1-CAM-positive tumorsJürgen Grünberg
Center for Radiopharmaceutical Science ETH PSI USZ, Paul Scherrer Institute, Villigen, Switzerland
Clin Cancer Res 11:5112-20. 2005.... - NanoPET imaging of [(18)F]fluoromisonidazole uptake in experimental mouse tumoursMatthias T Wyss
Center for Radiopharmaceutical Science of ETH, PSI and USZ, Paul Scherrer Institute, Villigen, Switzerland
Eur J Nucl Med Mol Imaging 33:311-8. 2006..The purpose of this study was to assess the potential and utility of ultra-high-resolution hypoxia imaging in various murine tumour models using the established hypoxia PET tracer [(18)F]fluoromisonidazole ([(18)F]FMISO)... - Imaging of renal carcinoma xenografts with 64Cu-labelled anti-L1-CAM antibody chCE7Ilse Novak-Hofer
Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232, Villigen, Switzerland
Eur J Nucl Med Mol Imaging 30:1066. 2003 - Performance evaluation of the 16-module quad-HIDAC small animal PET cameraJohn Missimer
Biomolecular Research and Center for Radiopharmaceutical Science of PSI, ETH and USZ, Life Sciences Division, Paul Scherrer Institute, 5232 Villigen, Switzerland
Phys Med Biol 49:2069-81. 2004..Reconstruction of a point source yields a resolution of 1.1 mm FWHM for all three components. The performance of the camera demonstrates its excellent suitability for the functional imaging of small animals... - Synthesis and preclinical evaluation of a folic acid derivative labeled with 18F for PET imaging of folate receptor-positive tumorsAndrea Bettio
Department of Chemistry and Applied Biosciences of ETH, Center for Radiopharmaceutical Science of ETH, PSI, and USZ, Zurich, Switzerland
J Nucl Med 47:1153-60. 2006..07 %ID/g (P = 0.001). CONCLUSION: This new 18F-labeled folic acid derivative is a promising tool for PET imaging of folate receptor-positive tumors... - Influence of ceftriaxone treatment on FDG uptake--an in vivo [18F]-fluorodeoxyglucose imaging study in soft tissue infections in ratsMatthias T Wyss
PET Center, Division of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland
Nucl Med Biol 31:875-82. 2004..The change of FDG uptake over time in treated and untreated infections is complex and further in vivo experiments have to be initiated to investigate the potential value of clinical FDG PET in therapy monitoring of infection... - Radiolabeling and in vitro and in vivo evaluation of [18F]-FE-DABP688 as a PET radioligand for the metabotropic glutamate receptor subtype 5Michael Honer
Animal Imaging Center PET, Center for Radiopharmaceutical Science of ETH, PSI and USZ, ETH Hoenggerberg, CH 8093 Zurich, Switzerland
Nucl Med Biol 34:973-80. 2007..FE-DABP688 was radiolabeled with fluorine-18 and characterized as a PET imaging agent for the metabotropic glutamate receptor subtype 5 (mGluR5)... - Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5Simon M Ametamey
Center for Radiopharmaceutical Science of ETH, PSI and USZ and Department of Chemistry and Applied Biosciences of ETH, CH 8093 Zurich, Switzerland
J Nucl Med 47:698-705. 2006.... - 18F-choline in experimental soft tissue infection assessed with autoradiography and high-resolution PETMatthias T Wyss
PET Center, Division of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland
Eur J Nucl Med Mol Imaging 31:312-6. 2004..Future studies are now needed to determine the degree of this limitation in human cancer patients... - Molecular imaging with PETSimon M Ametamey
Center for Radiopharmaceutical Science of ETH, PSI and USZ, Department of Chemistry and Applied Biosciences of ETH, CH-8093 Zurich, Switzerland
Chem Rev 108:1501-16. 2008 - Comparison of [18F]FDOPA, [18F]FMT and [18F]FECNT for imaging dopaminergic neurotransmission in miceMichael Honer
Center for Radiopharmaceutical Science of ETH, PSI and USZ, CH 8093 Zurich, Switzerland
Nucl Med Biol 33:607-14. 2006..This study describes our efforts to adopt the methodology of human Parkinson's disease (PD) PET studies to mice... - Whole animal copper flux assessed by positron emission tomography in the Long-Evans cinnamon rat--a feasibility studyKarl-Dimiter Bissig
Department of Clinical Pharmacology, University of Berne, 3010 Berne, Switzerland
Biometals 18:83-8. 2005..This trapping does however limit the utility of PET to measure whole animal copper flux... - Ionizing radiation antagonizes tumor hypoxia induced by antiangiogenic treatmentOliver Riesterer
Department of Radiation Oncology, University Hospital Zurich, , Switzerland
Clin Cancer Res 12:3518-24. 2006..Thus, the risk of treatment-induced hypoxia by inhibitors of angiogenesis exists but is kept minimal when combined with a cytotoxic treatment modality... - Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatmentMatthias J E Arlt
Klinikum rechts der Isar der Technischen Universitat Munchen, Institut für Experimentelle Onkologie und Therapieforschung, Ismaninger Strasse 22, D 81675 Munich, Germany
Cancer Res 66:936-43. 2006.... - A-186253, a specific antagonist of the alpha 4 beta 2 nAChRs: its properties and potential to study brain nicotinic acetylcholine receptorsValerie Itier
Department of Physiology, Medical Faculty, CMU, University of Geneva, 1, rue Michel Servet, CH 1211 Geneva 4, Switzerland
Neuropharmacology 47:538-57. 2004..While the A-186253 can be valuable to discriminate receptor subtypes, improvements of this molecule must be brought for in vivo measurements... - Synthesis and in vitro and in vivo evaluation of [11C]methyl-BIII277CL for imaging the PCP-binding site of the NMDA receptor by petMarko Kokic
Center for Radiopharmaceutical Science of the ETH, Paul Scherrer Institute and Division of Nuclear Medicine, University Hospital Zurich, CH-5232 Villigen PSI, Switzerland
J Recept Signal Transduct Res 22:123-39. 2002..36 mL/mL(tissue)/min and k2 = 0.37min(-1)) in pig cortex. [11C]methyl-BIII277CL, due to the lack of specificity in vivo, may not be a candidate for imaging the PCP-binding site of the NMDA receptor...